Performance of anti-Mullerian hormone (AMH) levels measured by Beckman Coulter Access AMH assay to predict oocyte yield following controlled ovarian stimulation for in vitro fertilization

被引:13
作者
Asada, Yoshimasa [1 ,2 ]
Tsuiki, Miyako [1 ]
Sonohara, Megumi [1 ]
Fukunaga, Noritaka [1 ,2 ]
Hattori, Yukio [1 ]
Inoue, Daichi [1 ]
Ito, Rie [1 ]
Hashiba, Yoshiki [1 ]
机构
[1] Asada Ladies Clin, Nagoya, Aichi, Japan
[2] Asada Inst Reprod Med, Kasugai, Aichi, Japan
关键词
anti-Mullerian hormone; Beckman Coulter Access assay; mature oocyte; oocyte yield; ovarian reserve;
D O I
10.1002/rmb2.12271
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Purpose We evaluated the performance of anti-Mullerian hormone (AMH) measured by the Beckman Coulter fully automated Access assay to predict oocyte yield following controlled ovarian stimulation (COS) for in vitro fertilization (IVF). Methods The correlation between the Access assay and the pre-mixing method with Generation II ELISA assay (Gen II pre-mix assay) was assessed using 230 blood samples. The relationship of AMH level measured by the Access assay and the actual number of oocytes retrieved following COS was assessed using 3296 IVF cycles. The performances of AMH, follicle stimulating hormone (FSH), and estradiol (E2) in predicting the responses to COS were also evaluated by constructing receiver operating characteristic (ROC) curves. Results The AMH levels measured just before oocyte retrieval by the Access assay and the number of oocytes retrieved following COS showed a good correlation with R = 0.655. The ROC analysis revealed that the sensitivity of AMH was comparable with or lower than that of E2 but higher than that of FSH. Conclusions With the improved Access AMH assays, AMH was as sensitive as E2 and could become an accurate marker of ovarian response to COS in more than 3000 Japanese IVF patients.
引用
收藏
页码:273 / 277
页数:5
相关论文
共 8 条
[1]   Pretreatment anti-Mullerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer [J].
Anderson, Richard A. ;
Rosendahl, Mikkel ;
Kelsey, Thomas W. ;
Cameron, David A. .
EUROPEAN JOURNAL OF CANCER, 2013, 49 (16) :3404-3411
[2]  
Asada Y, 2017, REPROD MED BIOL, V16, P364, DOI 10.1002/rmb2.12055
[3]   Antimullerian hormone: prediction of cumulative live birth in gonadotropin-releasing hormone antagonist treatment for in vitro fertilization [J].
Hamdine, Ouijdane ;
Eijkemans, Marinus J. C. ;
Lentjes, Eef G. W. ;
Torrance, Helen L. ;
Macklon, Nick S. ;
Fauser, Bart C. J. M. ;
Broekmans, Frank J. .
FERTILITY AND STERILITY, 2015, 104 (04) :891-+
[4]   Normal Ovarian Function and Assessment of Ovarian Reserve in the Survivor of Childhood Cancer [J].
Johnston, Robert J. ;
Wallace, W. Hamish B. .
PEDIATRIC BLOOD & CANCER, 2009, 53 (02) :296-302
[5]   Anti-Mullerian hormone (AMH): what do we still need to know? [J].
La Marca, A. ;
Broekmans, F. J. ;
Volpe, A. ;
Fauser, B. C. ;
Macklon, N. S. .
HUMAN REPRODUCTION, 2009, 24 (09) :2264-2275
[6]   The journey from the old to the new AMH assay: how to avoid getting lost in the values [J].
Nelson, S. M. ;
La Marca, A. .
REPRODUCTIVE BIOMEDICINE ONLINE, 2011, 23 (04) :411-420
[7]   Biomarkers of ovarian response: current and future applications [J].
Nelson, Scott M. .
FERTILITY AND STERILITY, 2013, 99 (04) :963-969
[8]   Dynamic antimullerian hormone levels during controlled ovarian hyperstimulation predict in vitro fertilization response and pregnancy outcomes [J].
Styer, Aaron K. ;
Gaskins, Audrey J. ;
Brady, Paula C. ;
Sluss, Patrick M. ;
Chavarro, Jorge E. ;
Hauser, Russ B. ;
Toth, Thomas L. .
FERTILITY AND STERILITY, 2015, 104 (05) :1153-+